Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.40 |
| ▸ | TUBB | P07437 | 5/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30483746 | 1.00 | RHEB (0.41) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL38660362 | 0.80 | TUBB4A (0.47) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2979916 | 0.80 | RHEB (0.41) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2085433 | 0.80 | TUBB4A (0.47) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL25748438 | 0.78 | RHEB (0.40) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30483766 | 0.78 | RHEB (0.40) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30712075 | 0.78 | KDM4E (0.45) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12034737 | 0.76 | PARP1 (0.41) | MAPK1KMT2AKDM4EALDH1A1 | |
| SCHEMBL8404367 | 0.74 | AHR (0.40) | RHEBP2RX7BRD4AHR | |
| SCHEMBL12309699 | 0.73 | BRD4 (0.41) | RHEBTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-27 | — | — | US | disclosed |
| CN-118715204-A | Compounds of formula (I) | 普赛洛私人有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2016007630-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN, LLC (US) | 2016-01-14 | — | — | WO | disclosed |
| EP-1161418-B1 | 1-ACYL-7-NITROINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHOTOCLEAVABLE PRECURSORS | MEDICAL RES COUNCIL (GB) | 2005-12-28 | — | — | EP | disclosed |
| US-6765014-B1 | DRUG DELIVERY OF NEUROACTIVE AMINO ACIDS OR METAL CHELATORS | MEDICAL RESEARCH COUNCIL (GB) | 2004-07-20 | — | — | US | disclosed |
| EP-1161418-A1 | 1-ACYL-7-NITROINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHOTOCLEAVABLE PRECURSORS | MEDICAL RESEARCH COUNCIL (GB) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000055133-A1 | 1-ACYL-7-NITROINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHOTOCLEAVABLE PRECURSORS | MEDICAL RESEARCH COUNCIL (GB) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | RHEB 673/4885TUBB4A 627/4885TUBB 472/4885 |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | CHRNA7, CHRNA2, CHRNA5 | RHEB 2671/4885TUBB4A 1075/4885TUBB 800/4885 |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNA7, CHRNA2, CHRNA6 | RHEB 2940/4885TUBB4A 1449/4885TUBB 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.